RESUMEN
INTRODUCTION: Oral mucositis (OM) is a severe side effect in patients undergoing anticancer therapies, which negatively impacts on their quality of life often leading to either the interruption of the therapy. Photobiomodulation (PBM) is emerging as an effective strategy allowing a faster wound healing. OBJECTIVES: This pilot study aims at verifying whether PBM modulates the inflammatory response in patients and its effect on the oral microbiome composition. MATERIALS AND METHODS: Buccal swabs were collected from four patients affected by OM, both on ulcerated and clinically healthy areas, before and on the last day of PBM therapy, as well as on the first day after treatment discontinuation. The concentration of 38 cytokines and the composition of oral microbiome were measured. RESULTS: Most of the pro-inflammatory cytokines were reduced, whereas anti-inflammatory cytokines resulted up-regulated by PBM. In addition, PBM influenced the composition of oral microbiome, by decreasing the amount of pathogenic species and promoting the growth of commensal bacteria. These changes were even more evident when separately analysing patients who clinically responded to PBM and the only patient who did not respond. CONCLUSIONS: PBM reduces inflammatory burden in patients affected by OM and positively influences the composition of the oral microbiome.
Asunto(s)
Bacterias/efectos de la radiación , Citocinas/metabolismo , Mediadores de Inflamación/metabolismo , Terapia por Luz de Baja Intensidad , Microbiota/efectos de la radiación , Mucosa Bucal/efectos de la radiación , Estomatitis/radioterapia , Bacterias/crecimiento & desarrollo , Disbiosis , Humanos , Mucosa Bucal/metabolismo , Mucosa Bucal/microbiología , Mucosa Bucal/patología , Proyectos Piloto , Estomatitis/metabolismo , Estomatitis/microbiología , Estomatitis/patología , Resultado del TratamientoRESUMEN
BACKGROUND: Gastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes the primary injury trigger, the interaction of oral microbial commensals with mucosal tissues could modify the response. It is not clear, however, whether chemotherapy and its associated treatments affect oral microbial communities disrupting the homeostatic balance between resident microorganisms and the adjacent mucosa and if such alterations are associated with mucositis. To gain knowledge on the pathophysiology of oral mucositis, 49 subjects receiving 5-fluorouracil (5-FU) or doxorubicin-based chemotherapy were evaluated longitudinally during one cycle, assessing clinical outcomes, bacterial and fungal oral microbiome changes, and epithelial transcriptome responses. As a control for microbiome stability, 30 non-cancer subjects were longitudinally assessed. Through complementary in vitro assays, we also evaluated the antibacterial potential of 5-FU on oral microorganisms and the interaction of commensals with oral epithelial tissues. RESULTS: Oral mucositis severity was associated with 5-FU, increased salivary flow, and higher oral granulocyte counts. The oral bacteriome was disrupted during chemotherapy and while antibiotic and acid inhibitor intake contributed to these changes, bacteriome disruptions were also correlated with antineoplastics and independently and strongly associated with oral mucositis severity. Mucositis-associated bacteriome shifts included depletion of common health-associated commensals from the genera Streptococcus, Actinomyces, Gemella, Granulicatella, and Veillonella and enrichment of Gram-negative bacteria such as Fusobacterium nucleatum and Prevotella oris. Shifts could not be explained by a direct antibacterial effect of 5-FU, but rather resembled the inflammation-associated dysbiotic shifts seen in other oral conditions. Epithelial transcriptional responses during chemotherapy included upregulation of genes involved in innate immunity and apoptosis. Using a multilayer epithelial construct, we show mucositis-associated dysbiotic shifts may contribute to aggravate mucosal damage since the mucositis-depleted Streptococcus salivarius was tolerated as a commensal, while the mucositis-enriched F. nucleatum displayed pro-inflammatory and pro-apoptotic capacity. CONCLUSIONS: Altogether, our work reveals that chemotherapy-induced oral mucositis is associated with bacterial dysbiosis and demonstrates the potential for dysbiotic shifts to aggravate antineoplastic-induced epithelial injury. These findings suggest that control of oral bacterial dysbiosis could represent a novel preventive approach to ameliorate oral mucositis.
Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/microbiología , Disbiosis/etiología , Microbiota/efectos de los fármacos , Mucosa Bucal/microbiología , Mucosa Bucal/patología , Estomatitis/etiología , Antineoplásicos/efectos adversos , Bacterias/efectos de los fármacos , Quimioterapia , Disbiosis/microbiología , Fluorouracilo/efectos adversos , Hongos/efectos de los fármacos , Humanos , Inflamación , Estudios Longitudinales , Boca/microbiología , Mucosa Bucal/efectos de los fármacos , Estudios Prospectivos , Estomatitis/microbiologíaRESUMEN
AIM: The study aims to assess the Mentha piperita leaf extract's effectiveness against oral pathogens. MATERIALS AND METHODS: The leaf extract of M. piperita was prepared using cold water method. The three microbial strains, i.e., Streptococcus mutans, Aggregatibacter actinomycetem-comitans, and Candida albicans were used as microbiological materials. Chlorhexidine 0.2% was used as positive control. The digital caliper was used to measure the zone of inhibition to know the antimicrobial activity at 24 and 48 hours. To compare the activity within and between the different microbial strains, one-way analysis of variance (ANOVA) was used. To analyze the data, Statistical Package for the Social Sciences (SPSS) software version of 21.0 was used. The p-value ≤0.05 was considered as statistically significant. RESULTS: Maximum inhibition zone was seen in both M. piperita extracts and 0.2% chlorhexidine with S. mutans at 24 and 48 hours, followed by A. actinomycetemcomitans, and C. albi-cans respectively. The statistical analysis ANOVA reveals the statistically significant association of M. piperita extracts with p-value <0.001. The comparison with 0.2% chlorhexidine at 24 hours showed a p-value of <0.04 and at 48 hours, it showed a p-value <0.001, which was statistically significant. CONCLUSION: The present study concluded that M. piperita showed antimicrobial activity against the oral microorganisms which are causing major less or more severe oral diseases and it can be administered as an alternative medicine for the conventional treatment. CLINICAL SIGNIFICANCE: The study results serve as a guide in selecting and providing information about the efficacy of M. piperita extracts to the dental professionals. The discovery of a potential herbal medication would be a great development in the field of antimicrobial therapies.
Asunto(s)
Aggregatibacter actinomycetemcomitans/efectos de los fármacos , Candida albicans/efectos de los fármacos , Mentha piperita/química , Extractos Vegetales/farmacología , Hojas de la Planta/química , Streptococcus mutans/efectos de los fármacos , Aggregatibacter actinomycetemcomitans/patogenicidad , Candida albicans/patogenicidad , Candidiasis Bucal/microbiología , Farmacorresistencia Bacteriana , Farmacorresistencia Fúngica , Humanos , Pruebas de Sensibilidad Microbiana/métodos , Estomatitis/microbiología , Streptococcus mutans/patogenicidadRESUMEN
Infectious stomatitis represents the most common oral cavity ailments. Current therapy is insufficiently effective because of the short residence time of topical liquid or semisolid medical formulations. An innovative application form based on bioadhesive polymers featuring prolonged residence time on the oral mucosa may be a solution to this challenge. This formulation consists of a mucoadhesive oral film with incorporated nanocomposite biomaterial that is able to release the drug directly at the target area. This study describes the unique approach of preparing mucoadhesive oral films from carmellose with incorporating a nanotechnologically modified clay mineral intercalated with chlorhexidine. The multivariate data analysis was employed to evaluate the influence of the formulation and process variables on the properties of the medical preparation. This evaluation was complemented by testing the antimicrobial and antimycotic activity of prepared films with the aim of finding the most suitable composition for clinical application. Generally, the best results were obtained with sample containing 20 mg of chlorhexidine diacetate carried by vermiculite, with carmellose in the form of nonwoven textile in its structure. In addition to its promising physicomechanical, chemical, and mucoadhesive properties, the formulation inhibited the growth of Staphylococcus and Candida; the effect was prolonged for tens of hours.
Asunto(s)
Antiinfecciosos/administración & dosificación , Carboximetilcelulosa de Sodio/administración & dosificación , Sistemas de Liberación de Medicamentos , Nanocompuestos/administración & dosificación , Estomatitis/tratamiento farmacológico , Antiinfecciosos/química , Materiales Biocompatibles/administración & dosificación , Materiales Biocompatibles/química , Carboximetilcelulosa de Sodio/química , Química Farmacéutica , Quitosano/química , Clorhexidina/administración & dosificación , Clorhexidina/química , Humanos , Boca/efectos de los fármacos , Boca/microbiología , Nanocompuestos/química , Polímeros/administración & dosificación , Polímeros/química , Estomatitis/microbiologíaRESUMEN
BACKGROUND: Curcumin (CUR) is a dietary spice and food colorant (E100). Its potent anti-inflammatory activity by inhibiting the activation of Nuclear Factor-κB is well established. METHODS: The aim of this study was to compare natural purified CUR (nCUR) with synthetically manufactured CUR (sCUR) with respect to their capacity to inhibit detrimental effects in an in vitro model of oral mucositis. The hypothesis was to demonstrate bioequivalence of nCUR and sCUR. RESULTS: The purity of sCUR was HPLC-confirmed. Adherence and invasion assays for bacteria to human pharyngeal epithelial cells demonstrated equivalence of nCUR and sCUR. Standard assays also demonstrated an identical inhibitory effect on pro-inflammatory cytokine/chemokine secretion (e.g., interleukin-8, interleukin-6) by Detroit pharyngeal cells exposed to bacterial stimuli. There was bioequivalence of sCUR and nCUR with respect to their antibacterial effects against various pharyngeal species. CONCLUSION: nCUR and sCUR are equipotent in in vitro assays mimicking aspects of oral mucositis. The advantages of sCUR include that it is odorless and tasteless, more easily soluble in DMSO, and that it is a single, highly purified molecule, lacking the batch-to-batch variation of CUR content in nCUR. sCUR is a promising agent for the development of an oral anti-mucositis agent.
Asunto(s)
Antibacterianos/farmacología , Antiinflamatorios/farmacología , Curcumina/farmacología , Células Epiteliales/efectos de los fármacos , Mucosa Bucal/efectos de los fármacos , Extractos Vegetales/farmacología , Estomatitis , Química Farmacéutica , Curcuma/química , Citocinas/metabolismo , Células Epiteliales/metabolismo , Humanos , Técnicas In Vitro , Mucosa Bucal/microbiología , Estomatitis/tratamiento farmacológico , Estomatitis/metabolismo , Estomatitis/microbiología , Equivalencia TerapéuticaRESUMEN
PURPOSE: Curcumin exerts its anti-inflammatory activity via inhibition of nuclear factor κB. Oropharyngeal epithelia and residing bacteria closely interact in inflammation and infection. This in vitro model investigated the effects of curcumin on bacterial survival, adherence to, and invasion of upper respiratory tract epithelia, and studied its anti-inflammatory effect. We aimed to establish a model, which could offer insights into the host-pathogen interaction in cancer therapy induced mucositis. METHODS: Moraxella catarrhalis (Mcat) and the oropharyngeal epithelial cell line Detroit 562 were used. Time-kill curves assessed the inhibition of bacterial growth and adherence assays and gentamicin protection assays determined the effect of curcumin-preincubated cells on bacterial adherence and invasion. Curcumin-mediated inhibition of pro-inflammatory activation by Mcat was determined via interleukin-8 concentrations in the supernatants. The synergistic role of secretory IgA (sIgA) on adherence was investigated. RESULTS: Curcumin was bactericidal at concentrations >50 µM. Preincubation of Detroit cells for 60 min demonstrated that concentrations >100 µM inhibited bacterial adherence. Together with sIgA, curcumin inhibited adherence at concentrations ≥50 µM. Both 100 and 200 µM curcumin significantly inhibited Mcat cell invasion. Finally, curcumin inhibited Mcat-induced pro-inflammatory activation by strongly suppressing IL-8 release. At a concentration of 200 µM, 10 min of curcumin exposure inhibited IL-8 release significantly, and complete suppression required a pre-exposure time of ≥45 min. CONCLUSION: Curcumin, in clinically relevant concentrations for topical use, displayed strong antibacterial effect against a facultative upper respiratory tract pathogen by inhibiting bacterial growth, adherence, invasion, and pro-inflammatory activation of upper respiratory tract epithelial cells in vitro.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Curcumina/farmacología , Inmunoglobulina A Secretora/administración & dosificación , Moraxella catarrhalis/efectos de los fármacos , Administración Tópica , Antiinflamatorios no Esteroideos/administración & dosificación , Adhesión Bacteriana/efectos de los fármacos , Línea Celular , Curcumina/administración & dosificación , Relación Dosis-Respuesta a Droga , Células Epiteliales/efectos de los fármacos , Células Epiteliales/microbiología , Humanos , Interleucina-8/metabolismo , Infecciones por Moraxellaceae/tratamiento farmacológico , Infecciones por Moraxellaceae/microbiología , Orofaringe/citología , Orofaringe/microbiología , Estomatitis/tratamiento farmacológico , Estomatitis/etiología , Estomatitis/microbiología , Factores de TiempoRESUMEN
Previous studies have shown anti-inflammatory potential of alkaline extract of the leaves of Sasa senanensis Rehder (SE). The aim of the present study was to clarity the molecular entity of SE, using various fractionation methods. SE inhibited the production of nitric oxide (NO), but not tumour necrosis factor-α by lipopolysaccharide (LPS)-stimulated mouse macrophage-like cells. Lignin carbohydrate complex prepared from SE inhibited the NO production to a comparable extent with SE, whereas chlorophyllin was more active. On successive extraction with organic solvents, nearly 90% of SE components, including chlorophyllin, were recovered from the aqueous layer. Anti-HIV activity of SE was comparable with that of lignin-carbohydrate complex, and much higher than that of chlorophyllin and n-butanol extract fractions. The CYP3A inhibitory activity of SE was significantly lower than that of grapefruit juice and chlorophyllin. Oral administration of SE slightly reduced the number of oral bacteria. When SE was applied to HPLC, nearly 70% of SE components were eluted as a single peak. These data suggest that multiple components of SE may be associated with each other in the native state or after extraction with alkaline solution.
Asunto(s)
Álcalis/administración & dosificación , Antiinflamatorios/administración & dosificación , Macrófagos/efectos de los fármacos , Extractos Vegetales/administración & dosificación , Sasa/química , Estomatitis/tratamiento farmacológico , Animales , Infecciones por Bacteroidaceae/tratamiento farmacológico , Infecciones por Bacteroidaceae/inmunología , Infecciones por Bacteroidaceae/microbiología , Línea Celular , Clorofilidas/farmacología , Citrus paradisi/química , Infecciones por VIH/tratamiento farmacológico , Humanos , Lignina/farmacología , Lipopolisacáridos/farmacología , Macrófagos/citología , Macrófagos/metabolismo , Masculino , Ratones , Microsomas Hepáticos/efectos de los fármacos , Óxido Nítrico/metabolismo , Porphyromonas gingivalis/efectos de los fármacos , Porphyromonas gingivalis/crecimiento & desarrollo , Ratas , Estomatitis/inmunología , Estomatitis/microbiología , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
The Brazilian commercial ethanol propolis extract, also formulated to ensure physical and chemical stability, was found to inhibit oral candidiasis in 12 denture-bearing patients with prosthesis stomatitis candidiasis association.
Asunto(s)
Antifúngicos/farmacología , Candida albicans/efectos de los fármacos , Candidiasis Bucal/prevención & control , Fitoterapia , Própolis/farmacología , Adulto , Anciano , Animales , Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Abejas , Brasil , Dentaduras , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Própolis/administración & dosificación , Própolis/uso terapéutico , Estomatitis/microbiologíaRESUMEN
The combined use of laser radiation and Radachlorine revealed the presence of correlation between the number of viable Streptococcus pyogenes cells and the concentration of photosensitizer (r=-0.62), time of irradiation (r=-0.75), as well as energy density (r=-0.80). The death of 100% of suspended S. pyogenes cells was observed at the concentration of Radachlorine reaching 14.4 mM and radiation power reaching 1 W, irrespective of energy density. Pulse and superpulse laser radiation, carried out simultaneously with the use of Radachlorine at a concentration of 1.8 microM, resulted in the death of 100% of S. pyogenes cells in vitro. On the experimental model of inflammation the application of 0.1% Radachlorine gel demonstrated higher effectiveness (in comparison with 0.35% Radachlorine solution) when used simultaneously with laser radiation, both continuous and superpulse (with energy density being 400 j/cm2 and power being 1 W). The use of these parameters in the treatment of the experimental foci of inflammation in the animals led to the complete elimination of S. pyogenes from infected tissues.
Asunto(s)
Rayos Láser , Fotoquimioterapia , Fármacos Fotosensibilizantes/uso terapéutico , Porfirinas/uso terapéutico , Estomatitis/tratamiento farmacológico , Infecciones Estreptocócicas/tratamiento farmacológico , Streptococcus pyogenes , Animales , Recuento de Colonia Microbiana , Modelos Animales de Enfermedad , Perros , Relación Dosis-Respuesta a Droga , Relación Dosis-Respuesta en la Radiación , Pruebas de Sensibilidad Microbiana , Fotoquimioterapia/métodos , Estomatitis/microbiología , Infecciones Estreptocócicas/microbiología , Streptococcus pyogenes/efectos de los fármacos , Streptococcus pyogenes/efectos de la radiaciónRESUMEN
Feline calicivirus (FCV) shedding and oral bacterial flora were monitored over a period of 22 months in a case of feline gingivostomatitis (FGS). The cat was treated daily with 50 mg thalidomide capsules by mouth, and 200 mg lactoferrin powder was applied directly to the lesions. Clinical signs began to resolve after 11 months when, in addition to treatment, the diet had been changed to an additive-free cat food supplemented with antioxidant vitamins A, D3 and E. Resolution of clinical signs of FGS coincided with the cessation of FCV shedding, and this is the first report documenting such an association. Which part of the treatment, if any, contributed to the cure requires further investigation.
Asunto(s)
Calicivirus Felino/aislamiento & purificación , Enfermedades de los Gatos/microbiología , Enfermedades de las Encías/veterinaria , Estomatitis/veterinaria , Administración Oral , Administración Tópica , Animales , Enfermedades de los Gatos/tratamiento farmacológico , Enfermedades de los Gatos/patología , Gatos , Enfermedad Crónica , Dieta , Enfermedades de las Encías/microbiología , Lactoferrina/administración & dosificación , Masculino , Pasteurella multocida/aislamiento & purificación , Estomatitis/microbiología , Talidomida/administración & dosificaciónRESUMEN
PURPOSE: Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer. The aim of this multicenter, double-blind, prospective, randomized trial was to evaluate the clinical efficacy of an economically viable antimicrobial lozenge (bacitracin, clotrimazole, and gentamicin [BcoG]) in the alleviation of radiation-induced mucositis in patients with head and neck cancer. PATIENTS AND METHODS: One hundred thirty-seven eligible patients were randomized to treatment with either antimicrobial lozenge (69 patients) or placebo lozenge (68 patients). The primary end point of the study was the time to development of severe mucositis from the start of radiotherapy. Secondary end points included severity and duration of mucositis, pain measurement, radiation therapy interruption, and quality of life. Mucositis was scored using a validated mucositis scoring system. RESULTS: Toxicity profiles were similar between the two arms of the study. The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61). There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays. CONCLUSION: This study was conducted on the basis of a pilot study that demonstrated the BCoG lozenge to be tolerable and microbiologically efficacious. A validated mucositis scoring system was used. However, in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis. Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.
Asunto(s)
Antibacterianos/administración & dosificación , Antiinfecciosos Locales/administración & dosificación , Bacitracina/administración & dosificación , Clotrimazol/administración & dosificación , Gentamicinas/administración & dosificación , Neoplasias de Cabeza y Cuello/radioterapia , Traumatismos por Radiación/prevención & control , Estomatitis/etiología , Estomatitis/prevención & control , Administración Oral , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Modelos Lineales , Masculino , Persona de Mediana Edad , Mucosa Bucal/efectos de los fármacos , Mucosa Bucal/microbiología , Estudios Prospectivos , Calidad de Vida , Dosificación Radioterapéutica , Estomatitis/microbiología , Resultado del TratamientoRESUMEN
BACKGROUND: Mucositis occurs in almost all radiotherapy-treated head and neck cancer patients, in approximately 75% of patients receiving hematopoietic marrow transplantation, and in approximately 40% of all patients who receive chemotherapy. Mucositis is painful, may affect all oral functions, and is a dose- and rate-limiting toxicity of therapy for cancer. Radiation-associated mucositis (onset, intensity, and duration) has been shown in recent clinical trials to be modified by the use of antibacterial/antifungal lozenges. PURPOSE: The aim of this collaborative two-center phase II study was to assess the toxicity and microbiologic efficacy of an economically viable antimicrobial lozenge in the management of patients receiving radiation therapy for head and neck cancer. MATERIALS AND METHODS: Seventeen patients scheduled to receive radical or postoperative radiotherapy were provided with bacitracin, clotrimazole, and gentamicin (BCoG) lozenges (one lozenge dissolved in the mouth qid from day 1 of radiotherapy until completion). Ease of use and palatability of the lozenges, patients' symptoms (swallowing and pain), and quantitative and qualitative microbiologic evaluation of an oral rinse collection was conducted at least once weekly during radiation therapy. RESULTS: No significant side effects were reported from the use of the lozenges. The lozenges were well tolerated at the beginning of treatment by all patients, with some minor difficulty associated with oral discomfort toward the end of the treatment. Microbiologic evaluation showed consistent elimination of yeast organisms in all patients. In four patients there was no growth of gram-negative bacilli on culture, whereas in two patients, fluctuating counts were seen, and one patient had increased counts. The remaining patients had significant reduction in the gram-negative bacilli counts. CONCLUSIONS: This study demonstrated that the BCoG lozenge is tolerable and microbiologically efficacious, achieving elimination of Candida in all patients and reduction in gram-negative flora in most patients. A phase III study is underway to evaluate the clinical efficacy of this lozenge.
Asunto(s)
Bacitracina/administración & dosificación , Carcinoma de Células Escamosas/radioterapia , Clotrimazol/administración & dosificación , Gentamicinas/administración & dosificación , Neoplasias de Cabeza y Cuello/radioterapia , Traumatismos por Radiación/tratamiento farmacológico , Estomatitis/tratamiento farmacológico , Administración Oral , Adulto , Anciano , Bacitracina/economía , Carcinoma de Células Escamosas/cirugía , Clotrimazol/economía , Femenino , Estudios de Seguimiento , Gentamicinas/economía , Neoplasias de Cabeza y Cuello/cirugía , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Mucosa Bucal/efectos de los fármacos , Mucosa Bucal/microbiología , Proyectos Piloto , Dosis de Radiación , Radioterapia Adyuvante/efectos adversos , Estomatitis/microbiología , Resultado del TratamientoRESUMEN
OBJECTIVE: To study the antibacterial activity of Chinese medicine kou-Kang mouthwash and its acute toxicity, and provide the basis of experiment and therapy for infectious diseases of the oral cavity. METHODS: Minimal inhibitory concentrations (MIC) of kou-Kang mouthwash were determined by the agar dilution method, and the acute toxicity was done. RESULTS: The range of MIC kou-Kang mouthwash against 27 Gram negative bacterial were 0.03-1.0 g.ml-1. MIC50 was 0.125 g.ml-1 and MIC90 was 0.125-0.5 g.ml-1. The range of MIC kou-Kang mouthwash against 21 Gram positive bacterial was 0.008-0.5 g.ml-1. The range of MIC50 and MIC90 were 0.015-0.125 g.ml-1 and 0.015-0.5 g.ml-1, respectively. The value of MIC was 0.015 g.ml-1 against candidia albicans. The acute toxic test indicated that the maximum tolerance dose was 417.6 g.kg-1 and 210 times as much as the clinical dose a day. No death of animals or toxicity and side-effect occurred in the test. CONCLUSION: Kou-Kang mouthwash shows a potent antibacterial activity against various pathogens of the oral cavity. Its antibiotic activity against Gram positive bacteria was 2-8 times stronger than that against Gram negative bacteria. It has low toxicity and can be used in clinical application.
Asunto(s)
Antibacterianos/farmacología , Medicamentos Herbarios Chinos/farmacología , Escherichia coli/efectos de los fármacos , Antisépticos Bucales , Staphylococcus aureus/efectos de los fármacos , Animales , Femenino , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Antisépticos Bucales/farmacología , Estomatitis/microbiologíaRESUMEN
Propolis is a resinous material collected by bees from the buds or other parts of plants. It is known for its biological properties, having antibacterial, antifungal and healing properties. The antifungal activity of propolis was studied in sensitivity tests on 80 strains of Candida yeasts: 20 strains of Candida albicans, 20 strains of Candida tropicalis, 20 strains of Candida krusei and 15 strains of Candida guilliermondii. The yeasts showed a clear antifungal activity with the following order of sensitivity: C. albicans > C. tropicalis > C. krusei > C. guilliermondii. Patients with full dentures who used a hydroalcoholic propolis extract showed a decrease in the number of Candida.
Asunto(s)
Antifúngicos/farmacología , Candida/efectos de los fármacos , Extractos Vegetales/farmacología , Própolis/farmacología , Humanos , Pruebas de Sensibilidad Microbiana , Extractos Vegetales/uso terapéutico , Própolis/uso terapéutico , Estomatitis/tratamiento farmacológico , Estomatitis/microbiología , Estomatitis Subprotética/dietoterapia , Estomatitis Subprotética/microbiologíaRESUMEN
OBJECTIVE: The purpose of this animal study was to determine whether IB-367, an antimicrobial peptide, is able to ameliorate oral mucositis by reducing microflora densities on the mucosal surfaces of the mouth. STUDY DESIGN: Oral mucositis was induced in hamsters by intraperitoneal injection of 5-fluorouracil followed by superficial abrasion of the buccal mucosa. A test formulation was applied topically to the buccal mucosa 5 or 6 times per day starting 6 to 8 hours before abrasion. RESULTS: Mucositis scores were significantly lower (P < .05) in hamsters given formulations containing 0.5 or 2.0 mg/mL of IB-367 than in placebo-treated controls. Treatment with IB-367 produced a more than 100-fold reduction in oral microflora densities. In a second experiment, treatment of hamsters with a formulation containing IB-367 at 0.12, 0.5 or 2.0 mg/mL resulted in a dose-dependent reduction in mucositis severity. CONCLUSION: The results indicate that reduction of local microflora densities through use of IB-367 may improve clinical outcomes in patients at risk for the development of oral mucositis.
Asunto(s)
Antiinfecciosos Locales/uso terapéutico , Mucosa Bucal/microbiología , Proteínas/uso terapéutico , Estomatitis/tratamiento farmacológico , Animales , Antiinfecciosos Locales/administración & dosificación , Péptidos Catiónicos Antimicrobianos , Bacillus/efectos de los fármacos , Recuento de Colonia Microbiana , Cricetinae , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Escherichia coli/efectos de los fármacos , Fluorouracilo , Masculino , Mesocricetus , Pasteurella/efectos de los fármacos , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/uso terapéutico , Péptidos , Proteínas/administración & dosificación , Proteus mirabilis/efectos de los fármacos , Estadísticas no Paramétricas , Estomatitis/inducido químicamente , Estomatitis/microbiología , Streptococcus/efectos de los fármacosRESUMEN
Mucositis can be the major dose-limiting toxicity during the adminstration of certain types of chemotherapy, especially 5-fluorouracil, methotrexate and doxorubicin. Infection probably plays a role after initial inflammatory changes occurs in the mucous membranes of the mouth after chemotherapy, especially if the patient becomes neutropenic. The issues addressed in this paper following a review of the literature are whether surveillance cultures can be helpful to avoid mucositis or at least predict who will be at risk for its development and whether this will be a help in decisions on the antimicrobial treatment that should be given if mucositis develops. Bacterial, fungal and viral causes of mucositis have been identified. The simplest to deal with is viral, since if herpes simplex is identified it should be treated with acyclovir; in the case of allogeneic bone marrow transplants acyclovir is usually given prophylactically. Fungal organisms almost certainly play a part; especially if a Candida species, particularly Candida tropicalis, is identified in surveillance cultures, it is probably important. The significance of bacterial pathogens in surveillance cultures is more difficult to sort out except for Pseudomonas aeruginosa, which almost always predicts for eventual systemic infection, especially bacteraemia. The poor overall predictive value (both positive and negative) for surveillance cultures and their significant expense do not support their routine use in 1997.
Asunto(s)
Antibacterianos/uso terapéutico , Antineoplásicos/efectos adversos , Estomatitis/inducido químicamente , Estomatitis/prevención & control , Antibacterianos/farmacología , Antineoplásicos/uso terapéutico , Ensayos Clínicos como Asunto , Farmacorresistencia Microbiana , Humanos , Pruebas de Sensibilidad Microbiana , Mucosa Bucal/efectos de los fármacos , Neoplasias/tratamiento farmacológico , Pronóstico , Estomatitis/tratamiento farmacológico , Estomatitis/microbiologíaRESUMEN
A double blind, randomized study comprising 60 patients was undertaken to compare the efficacy of ornidazole to that of phenoxymethylpenicillin in the treatment of orofacial infections. Thirty patients received ornidazole 500 mg orally every 12 h for seven days and were all cured in less than seven days. Five of the 30 patients receiving penicillin, 800 mg orally every 12 h for seven days, did not respond satisfactorily to the treatment given. In two of these instances, beta-lactamase-producing penicillin-resistant Bacteroides strains were isolated. In the present study, ornidazole was found to be more efficient than penicillin in the treatment of orofacial infections. Anaerobes were isolated from all specimens except four that yielded no growth. Anaerobes only were isolated from 65% of the specimens. Since ornidazole was efficient in all cases when given, it is concluded that anaerobic bacteria are the causal pathogens in most orofacial infections.